Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Data not reported for 35 participantsTertiary care centre (University Hospital of Heidelberg)(1) Age, (2) gender, (3) IBD status, (4) dominant stenosis, (5) Mayo risk score, (6) itch(1) Medical outcomes study 36-item short form survey†Haapamäki 2015Finland**Cross-sectional34154%4370%Asymptomatic = 45%ERC-score mean(SD): 5.9 (3.4)Tertiary referral centre (The Endoscopy Unit of Helsinki University Central Hospital)(1) Age, (2) gender, (3) symptoms(1) 15D instrument†Kempinska-Podhorodecka 2017Poland**Cross-sectional26766%55‡NRMedian ALP = 354 U/LTwo medical centres in Poland(1) Vitamin D receptor polymorphisms(1) Medical outcomes study 36-item short form survey†(2) PBC-40†(3) PBC-27†Raszeja-Wyszomirska 2015aPoland*Cross-sectional3367%3561%Cirrhosis = 7%,Mean ALP = 239 U/LA single tertiary centre(1) Fragility fractures(1) Medical outcomes study 36-item short form survey†(2) PBC-40†(3) PBC-27†Raszeja-Wyszomirska 2015bPoland*Cross-sectional10272%3672%Cirrhosis = 33%A medical institution in Warsaw, Poland(1) Age, (2) gender, (c) cirrhosis, (d) IBD status(1) Medical outcomes study 36-item short form survey†(2) PBC-40†(3) PBC-27†Tarter 1991USA*Cross-sectional5242%¥41¥NRChild: Pugh class:A = 49%, B = 38%, C = 14%Presbyterian University Hospital of the University of Pittsburgh Health Sciences Center(1) Child’s-Pugh class(1) Sickness Impact Profile†Wunsch 2016Poland**Cross-sectional11565%35NRMean ALP = 299 U/LChild: Pugh class: A = 53%, B = 40%,C = 7%Liver Unit (Pomeranian Medical University) and the Liver and Internal Medicine Unit (Medical University of Warsaw)(1) Serum autotaxin(1) Medical outcomes study 36-item short form survey†(2) PBC-40†(3) PBC-27†Younossi 2000USA*Cross-sectional2927%¥55¥NRNo cirrhosis = 36%¥Child: Pugh class¥:A = 35%, B = 22%, C = 2%NR(1) Age, (2) bilirubin, (3) Child’s-Pugh class(1) Medical outcomes study 36-item short form survey†(2) Chronic liver disease questionnaire†IBD inflammatory bowel disease, NR not reported, ALP alkaline phosphatase◊Low quality = *, Moderate quality = **, High quality = ***. †Multi-dimensional quality of life questionnaire. ¥Value based on whole sample (including other disease groups). ‡ Median value

Source: Study characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis not reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Quality of life in primary sclerosing cholangitis: a systematic review

Source: Article title.

In addition, many studies did not report data in a format suitable for meta-analysis (e.g.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Quality of life in primary sclerosing cholangitis: a systematic review

Systematic review · Health and Quality of Life Outcomes · 2021

Original publication title

Quality of life in primary sclerosing cholangitis: a systematic review

Elena Marcus; Paddy Stone; Anna-Maria Krooupa; Douglas Thorburn; Bella Vivat

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The limited findings from included studies suggest that markers of disease progression used in clinical trials may not reflect the experiences of people with PSC. This highlights the importance for clinical research studies to assess QoL alongside clinical and laboratory-based outcomes. A valid and responsive PSC-specific measure of QoL, to adequately capture all issues of importance to people with PSC, would therefore be helpful for clinical research studies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Primary sclerosing cholangitis (PSC) is a rare bile duct and liver disease which can considerably impact quality of life (QoL). As part of a project developing a measure of QoL for people with PSC, we conducted a systematic review with four review questions. The first of these questions overlaps with a recently published systematic review, so this paper reports on the last three of our initial four questions: (A) How does QoL in PSC compare with other groups?, (B) Which attributes/factors are associated with impaired QoL in PSC?, (C) Which interventions are effective in improving QoL in people with PSC?.

Source: Background

Abstract: What methods does the paper describe?

We systematically searched five databases from inception to 1 November 2020 and assessed the methodological quality of included studies using standard checklists.

Source: Methods

Abstract: Results

We identified 28 studies: 17 for (A), ten for (B), and nine for (C). Limited evidence was found for all review questions, with few studies included in each comparison, and small sample sizes. The limited evidence available indicated poorer QoL for people with PSC compared with healthy controls, but findings were mixed for comparisons with the general population. QoL outcomes in PSC were comparable to other chronic conditions. Itch, pain, jaundice, severity of inflammatory bowel disease, liver cirrhosis, and large-duct PSC were all associated with impaired QoL.

No associations were found between QoL and PSC severity measured with surrogate markers of disease progression or one of three prognostic scoring systems. No interventions were found to improve QoL outcomes.

Source: Results

Abstract: Conclusion

The limited findings from included studies suggest that markers of disease progression used in clinical trials may not reflect the experiences of people with PSC. This highlights the importance for clinical research studies to assess QoL alongside clinical and laboratory-based outcomes. A valid and responsive PSC-specific measure of QoL, to adequately capture all issues of importance to people with PSC, would therefore be helpful for clinical research studies.

Source: Conclusion
Authors’ abstract

Background

Primary sclerosing cholangitis (PSC) is a rare bile duct and liver disease which can considerably impact quality of life (QoL). As part of a project developing a measure of QoL for people with PSC, we conducted a systematic review with four review questions. The first of these questions overlaps with a recently published systematic review, so this paper reports on the last three of our initial four questions: (A) How does QoL in PSC compare with other groups?, (B) Which attributes/factors are associated with impaired QoL in PSC?, (C) Which interventions are effective in improving QoL in people with PSC?.

Methods

We systematically searched five databases from inception to 1 November 2020 and assessed the methodological quality of included studies using standard checklists.

Results

We identified 28 studies: 17 for (A), ten for (B), and nine for (C). Limited evidence was found for all review questions, with few studies included in each comparison, and small sample sizes. The limited evidence available indicated poorer QoL for people with PSC compared with healthy controls, but findings were mixed for comparisons with the general population. QoL outcomes in PSC were comparable to other chronic conditions. Itch, pain, jaundice, severity of inflammatory bowel disease, liver cirrhosis, and large-duct PSC were all associated with impaired QoL.

No associations were found between QoL and PSC severity measured with surrogate markers of disease progression or one of three prognostic scoring systems. No interventions were found to improve QoL outcomes.

Conclusion

The limited findings from included studies suggest that markers of disease progression used in clinical trials may not reflect the experiences of people with PSC. This highlights the importance for clinical research studies to assess QoL alongside clinical and laboratory-based outcomes. A valid and responsive PSC-specific measure of QoL, to adequately capture all issues of importance to people with PSC, would therefore be helpful for clinical research studies.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12955-021-01739-3.

Publication and source details

Original title: Quality of life in primary sclerosing cholangitis: a systematic review

Elena Marcus; Paddy Stone; Anna-Maria Krooupa; Douglas Thorburn; Bella Vivat

Health and Quality of Life Outcomes · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/501100012350British Liver Trusthttp://dx.doi.org/10.13039/501100000654Marie CurieMCCC-FCH-13-UStone Paddy

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:14:29.427777+00:00

DOI: 10.1186/s12955-021-01739-3 · PMC7981996